Gene Therapy Market 2028 By Vector, Indication ), Delivery Mode | The Insight Partners

report image

Gene Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Vector ( Non-Viral Vectors, Viral Vectors ); Indication ( Neurological Diseases, Cancer, Duchenne Muscular Dystrophy, Hepatological Diseases, Other Indications (Retinal Diseases, Beta-Thalassemia) ); Delivery Mode ( In-Vivo, Ex-Vivo )

Report Code: TIPHE100001165 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming


Gene therapy is an innovative treatment method that uses genes for the treatment of disease. In the future, it is anticipated that this technique may allow healthcare professionals to treat several chronic diseases by inserting a gene into a patient's cells instead of using different drugs or surgery. Gene therapy is a promising treatment alternative for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections). This method still remains risky and is under research to make sure that it will be safe and effective. Gene therapy is now being tested only for diseases that have no other cures. With the increase in advanced therapies and gene delivery technologies, the gene therapy market is growing..


The "Global Gene Therapy Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the gene therapy market with detailed market segmentation by vector, indication, delivery mode and geography. The report provides key statistics on the market status of the leading gene therapy market players and offers key trends and opportunities in the market.


  • Based on vector, the global gene therapy market is segmented into non-viral vectors, and viral vectors.
  • On the basis of indication, the market is segmented into neurological diseases, cancer, duchenne muscular dystrophy, hepatological diseases, other indications (retinal diseases, and beta-thalassemia.
  • Based on delivery mode, the market is bifurcated into in-vivo, and ex-vivo.



  • Rising prevalence of cancer.
  • Increasing number of product approvals .
  • Increasing funds for gene therapy research.


  • High cost of gene therapy


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The gene therapy market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Gene therapy market in these regions.


COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and medical industry in various countries due to lockdowns, travel bans, and business shutdowns.

Various healthcare research centers are working only for research on COVID-19 therapeutics. Few companies have already announced possible delays in product deliveries and slump in future sales of their products.

Further as per the UK's Cell and Gene Therapy (CGT) Catapult a centre of excellence for the cell and gene therapy industry, the number of advanced therapy medicinal product (ATMP) clinical trials continued to grow in 2020 despite the tremendous impact of COVID-19. ATMPs are therapeutic products including Gene Therapy Medicinal Products (GTMPs), Tissue Engineered Products (TEPs), somatic Cell Therapy Medicinal Products (sCTMPs) and others. the CGT Catapult also reported that the number of ongoing ATMP trials in the UK during 2020 was 154, which is an increase of 20% from 2019 (127).


The report covers key developments in the gene therapy market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from gene therapy market are anticipated to lucrative growth opportunities in the future with the rising demand for gene therapy in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the gene therapy market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  • Biogen
  • Spark Therapeutics, Inc.
  • MolMed S.p.A.
  • Orchard Therapeutics plc.
  • Human Stem Cells Institute
  • F. Hoffmann-La Roche Ltd.
  • Bluebird Bio, Inc.
  • Novartis AG

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

The List of Companies

1. Biogen
3. Spark Therapeutics, Inc.
4. MolMed S.p.A.
5. Orchard Therapeutics plc.
7. Human Stem Cells Institute
8. F. Hoffmann-La Roche Ltd.
9. Bluebird Bio, Inc.
10. Novartis AG
11. Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
12. UniQure N.V.
13. Shire Plc
14. Cellectis S.A.
15. Sangamo Therapeutics, Inc.
16. Orchard Therapeutics
17. Gilead Lifesciences, Inc.
18. Benitec Biopharma Ltd.
19. Sibiono GeneTech Co., Ltd.
20. Shanghai Sunway Biotech Co., Ltd.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount